{"id":"rasagiline-pharmacodynamics","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Nausea"},{"rate":"3-5","effect":"Dyspepsia"},{"rate":"2-5","effect":"Orthostatic hypotension"},{"rate":"3-5","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL887","moleculeType":"Small molecule","molecularWeight":"171.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By selectively inhibiting MAO-B, rasagiline reduces the enzymatic degradation of dopamine in the striatum and other brain regions affected by Parkinson's disease. This leads to increased dopamine availability, which helps restore motor function and reduce parkinsonian symptoms. The drug may also have neuroprotective properties independent of its MAO-B inhibition.","oneSentence":"Rasagiline is a selective monoamine oxidase type B (MAO-B) inhibitor that increases dopamine levels in the brain by preventing its breakdown.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:54.314Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease (early stage, as monotherapy)"},{"name":"Parkinson's disease (advanced stage, as adjunctive therapy with levodopa)"}]},"trialDetails":[{"nctId":"NCT05523570","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension","status":"COMPLETED","sponsor":"Guangzhou Henovcom Bioscience Co. Ltd.","startDate":"2022-08-22","conditions":"Parkinson's Disease","enrollment":34},{"nctId":"NCT00492336","phase":"PHASE4","title":"Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2007-01","conditions":"Schizophrenia","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"rasagiline (Pharmacodynamics)","genericName":"rasagiline (Pharmacodynamics)","companyName":"University of Maryland, Baltimore","companyId":"university-of-maryland-baltimore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rasagiline is a selective monoamine oxidase type B (MAO-B) inhibitor that increases dopamine levels in the brain by preventing its breakdown. Used for Parkinson's disease (early stage, as monotherapy), Parkinson's disease (advanced stage, as adjunctive therapy with levodopa).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}